U.S. Markets close in 10 mins.

Array BioPharma Inc. (ARRY)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.685+0.195 (+2.603%)
As of 3:50PM EDT. Market open.
People also watch
EXELARQLCLDXRIGLFOLD
Full screen
Previous Close7.490
Open7.450
Bid7.670 x 4500
Ask7.680 x 900
Day's Range7.330 - 7.750
52 Week Range3.100 - 13.400
Volume2,172,505
Avg. Volume3,489,752
Market Cap1.31B
Beta1.74
PE Ratio (TTM)-10.67
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Array BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : ARRY-US : July 24, 2017
    Capital Cube4 days ago

    Array BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : ARRY-US : July 24, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Array BioPharma, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • Zacks8 days ago

    New Strong Sell Stocks for July 20th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • American City Business Journals10 days ago

    Colorado biotech makes deal with industry giant

    A Boulder biotech said it's made a deal with an industry giant to develop drugs for autoimmune disorders. Array BioPharma Inc. (ARRY) said it's made a deal with giant Amgen Inc. (AMGN) of Thousand Oaks, California to take advantage of Array's inflammatory disease discoveries. "The identification of this novel target, along with our team's deep experience in kinase inhibitor chemistry, gives us confidence that our efforts will result in a drug which will address a significant unmet medical need for patients with inflammatory disease," said Nicholas Saccomano, chief scientific officer at Array, in a statement.